Assessment of the Cost of Fine-Needle Aspiration Cytology as a Diagnostic Tool in Patients With Thyroid Nodules

Archive ouverte

Borget, I | Vielh, P | Leboulleux, S | Allyn, M | Iacobelli, Sylviane | Schlumberger, M | de Pouvourville, Gérard

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. Fine-needle aspiration cytology (FNAC) is the reference diagnostic tool in patients with thyroid nodules. Because the true diagnosis is based on histopathologic findings, the final diagnosis of nodules not operated on is postponed, impacting the cost. We Aim :ed to determine the cost of FNAC by taking account of diagnostic mistakes, failures, and follow-up of patients who did not have surgery.A Markov model described the management of patients according to initial cytopathologic results. Estimates for accuracy values and follow-up were derived from a retrospective study of 624 patients. Costs were computed from the hospital perspective. Sensitivity analyses were performed. Of the lesions, 381 were cytopathologically classified as benign, 15 as malignant, 57 as "suspicious," and 171 as unsatisfactory. The cost of diagnosis was 1,145 euros . Cost was significantly affected by the unsatisfactory specimen percentage (27.4%), without which the cost would be reduced by 35.5%, to euros 738. Cost depends on cytopathologist performance and the unsatisfactory rate. In the future, routine ultrasound guidance and on-site assessment of cytopathologic adequacy would help reduce costs.

Consulter en ligne

Suggestions

Du même auteur

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal

Archive ouverte | Borget, I. | CCSD

International audience. INTRODUCTION: The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen) are well established as an alternative stimulation procedure to thyroid hormone withdraw...

Editorial : Calcitonin determination in patients with nodular thyroid disease

Archive ouverte | Borget, I | CCSD

International audience

How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer

Archive ouverte | Schlumberger, M | CCSD

International audience. Recombinant human TSH (rhTSH) is used in patients who have had surgery for thyroid cancer but are at low risk of recurrence. The rhTSH is used for the preparation of postoperative administrat...

Chargement des enrichissements...